Susquehanna Initiates Coverage on BMP Sunstone Corporation (BJGP) with a Positive
More News related to BJGP
- Notable Analyst Rating Changes 6/24: FCX, BDK, DB, EMC Upgraded; WFR, BA, CTRP Downgraded
- Oppenheimer Initiates Coverage on BMP Sunstone (BJGP) with an Outperform
- BMP Sunstone to be Featured on SIG's 'China Healthcare On Call' Conference Call Series
- After-Hours Movers 5/18: HIMX, TRID, KLIC Higher; APP, MHO, PVA, ENP, IVZ Lower
- BMP Sunstone (BJGP) Reports Q1 Adj-EPS of $0.07; Backs FY09 Outlook
Susquehanna initiates coverage on BMP Sunstone Corporation (Nasdaq: BJGP) with a Positive. Price target $8.00.
Susquehanna analyst says, "We are initiating coverage on BJGP with a Positive rating and an $8 price target. BJGP is a sales and marketing driven specialty pharma company with a differentiated value proposition through its three main lines of businesses in China: 1) BMP China: prescription drug (Rx) registration, marketing, and distribution for multinational drug companies; 2) Sunstone: branded domestic OTC and Rx products focusing on pediatric and women's health; and 3) Wanwei, Rongheng, and GPC: pharmaceutical distribution."
BMP Sunstone Corporation is a pharmaceutical and over-the-counter (OTC) manufacturing, marketing and distribution company. Through its subsidiary, Sunstone (Tangshan) Pharmaceutical Co., Ltd. (Sunstone), the Company manufactures, markets and distributes OTC products in China.
Related Categories
New CoverageStocks Mentioned
-0.09Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
